CareRx (29C1) AI Stock Analysis

CareRx

(Frankfurt:29C1)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Profitable growth and cash generationThe return to profitability alongside strong revenue growth indicates a materially improved earnings base. Positive free cash flow and high cash conversion provide internal funding for operations, debt service, and selective growth, supporting resilience over the next several quarters.

Negative Factors

Thin operating marginsAlthough CareRx is profitable, its modest operating margins leave limited protection if costs rise or volumes soften. Small changes in reimbursement, service efficiency, or operating expenses can therefore produce disproportionate effects on net income and cash generation.

CareRx (29C1) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 213.76M
Dividend Yield: 2.39%
Average Volume (3M): ―
Price to Earnings (P/E): 7.9
Beta (1Y): 0.20
Revenue Growth: -3.11%
EPS Growth: ―
Country: Germany
Employees: 1,483
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Care Facilities

CareRx Business Overview & Revenue Model

Company Description

CareRx Corporation, operating with its subsidiaries, specializes in delivering tailored pharmaceutical services to Canada's senior demographic. The company manages a vast network of medication dispensing facilities, which are responsible for providin...

CareRx Earnings Call Summary

Earnings Call Date:Jul 28, 2026(Q2-2026)|% Change Since:0.73%|Next Earnings Date:Nov 03, 2026

Earnings Call SentimentNeutral

The call presented a mix of positive operational and commercial progress (modest revenue and bed growth, a material ~3,000-bed contract win, dividend increase, ongoing efficiency actions and clinical/brand recognition) alongside near-term financial headwinds (a ~$2.0M funding hit from Ontario ward-bed changes, lower net income, slight margin compression, reduced quarter-end cash and higher net debt). Management expects the 3,000-bed win to be accretive over time and recovery of the ward-bed impact only after redevelopment in 2027. Overall the company shows constructive operational momentum but faces identifiable short-term funding and liquidity pressures.

Positive Updates

Revenue and Bed Growth

Q2 revenue $93.6M vs $91.4M in Q2 2025, up ~2.4% YoY; average beds serviced 91,719 vs 90,048 in Q2 2025, up ~1.9% (1,671 net beds).

Negative Updates

Ontario Ward Bed Funding Change

Change in funding for certain unoccupied ward beds effective April 1, 2026; management expects a full-year top-line impact of approximately $2.0M, with roughly $667K of the impact felt in Q2; recovery contingent on redevelopment of ward beds and not expected to be fully realized until late 2027.

Company Guidance

Management guided that the Ontario ward‑bed funding change will be a roughly $2.0M headwind for 2026 (about $667k hit was realized in Q2), with the company expecting to recapture that revenue once ward rooms are redeveloped—likely by late 2027; they also confirmed semaglutide generic supply/margin benefits are expected to materialize in 2027. They will onboard approximately 3,000 retirement beds in Q3 (all onboarding to complete within the quarter, with the full revenue/EBITDA benefit showing in Q4) and remain focused on an organic target of 6,000–8,000 bed additions by year‑end (about halfway to the low end today). Key Q2 metrics cited alongside this guidance: revenue $93.6M (vs. $91.4M LY), adjusted EBITDA $8.0M (margin 8.6% vs. 8.8% LY), net income ≈ $0.4M (vs. $0.6M LY), cash from operations $3.7M, cash $9.6M, net debt $29.1M (net debt/adjusted EBITDA 0.9x), and a 10% dividend increase to $0.022/share (payable Oct 8; $1.3M of dividends paid subsequent).

CareRx Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:29C1 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TSE:EXE	73Outperform	CAD 2.53B	20.13	36.33%	1.96%	31.14%	34.48%
TSE:NLH	71Outperform	CAD 43.66M	23.60	6.95%	―	18.35%	1021.05%
TSE:DR	62Neutral	CAD 237.42M	8.22	45.36%	2.45%	2.64%	-56.04%
TSE:WELL	62Neutral	CAD 1.07B	165.22	0.44%	―	38.54%	―
TSE:SIA	56Neutral	CAD 2.18B	37.83	6.58%	4.76%	16.11%	31.75%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

* Healthcare Sector Average

Performance Comparison

DE:29C1 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:29C1	Carerx Corporation	2.08	-0.07	-3.12%
TSE:EXE	Extendicare Inc.	26.57	10.57	66.03%
TSE:NLH	Nova Leap Health	0.50	0.22	78.57%
TSE:SIA	Sienna Senior Living	19.67	1.39	7.57%
TSE:DR	Medical Facilities Corp	14.68	0.56	3.95%
TSE:WELL	Well Health Technologies	4.18	-0.98	-18.99%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

CareRx AI Stock Analysis